| Literature DB >> 26366081 |
Bullo Saifullah1, Mohd Zobir B Hussein1.
Abstract
Entities:
Keywords: bioimaging; biosensors; drug delivery; inorganic nanolayers; layered double hydroxides; layered hydroxy salts
Mesh:
Substances:
Year: 2015 PMID: 26366081 PMCID: PMC4562743 DOI: 10.2147/IJN.S72330
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Applications of inorganic nanolayers.
Figure 2Schematic representation of the brucite structure.
Notes: (A) Side and (B) top view of the layer. Reprinted from Arizaga GG, Satyanarayana KG, Wypych F. Layered hydroxide salts: synthesis, properties and potential applications. Solid State Ionics. 2007;178:1143–1162, Copyright 2007, with permission from Elsevier.11
Figure 3Schematic representation of the structure of layered double hydroxide.
Notes: (A) Side and (B) top view of the layer. Reprinted from Arizaga GG, Satyanarayana KG, Wypych F. Layered hydroxide salts: synthesis, properties and potential applications. Solid State Ionics. 2007;178:1143–1162, Copyright 2007, with permission from Elsevier.11
Figure 4Structures of zinc hydroxide nitrate.
Notes: (A) Side view and (B) top view. Reprinted from Arizaga GG, Satyanarayana KG, Wypych F. Layered hydroxide salts: synthesis, properties and potential applications. Solid State Ionics. 2007;178:1143–1162, Copyright 2007, with permission from Elsevier.11
Figure 5Schematic representation of ion-exchange process.
Figure 6Possible chemiluminescence mechanism for the Co(II)-ethylenediaminetetraacetic acid (EDTA)-intercalated Mg/Al layered double hydroxide (LDH)-enhanced luminol–H2O2 system.
Note: Reprinted from Zhang LJ, Chen YC, Zhang AM, Lu C. Highly selective sensing of hydrogen peroxide based on cobalt-ethylenediaminetetraacetate complex intercalated layered double hydroxide-enhanced luminol chemiluminescence. Sens Actuators B Chem. 2014;193:752–758, Copyright 2014, with permission from Elsevier.82
Figure 7CytoViva microscopy images of MCF-7 cells incubated with Y2O3:Er3+, Yb3+@SiO2@LDH-5-FU at 100 mg·mL−1 for different time durations of 0.5 hour, 4 hours, and 24 hours.
Note: Reproduced from Chen C, Yee LK, Gong H, Zhang Y, Xu R. A facile synthesis of strong near infrared fluorescent layered double hydroxide nanovehicles with an anticancer drug for tumor optical imaging and therapy. Nanoscale. 2013;5:4314–4320, with permission of The Royal Society of Chemistry.95
Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; LDH, layered double hydroxide; 5-FU, fluorouracil.
Figure 8Solid-state absorbance spectra of Zn/Al-NO3, organic sunscreen guest cinnamic acid (CA), and the corresponding nanocomposite.
Note: Reprinted with permission from Mohsin SM, Hussein MZ, Sarijo SH, Fakurazi S, Arulselvan P, Taufiq-Yap YH. Characterisation and cytotoxicity assessment of UV absorbers-intercalated zinc/aluminium-layered double hydroxides on dermal fibroblast cells. Sci Adv Mater. 2014;6:648–658, Copyright © American Scientific Publishers.101
Abbreviation: UV, ultraviolet.
Figure 9Various antituberculosis nanodelivery formulations based on antituberculosis drugs, para-aminosalicylic acid, and isoniazid with various inorganic nanolayers.
Abbreviations: LDHs, layered double hydroxides; ZnLHs, zinc layered hydroxides.
Figure 10Confocal microscopic images of intracellular localization in NSC 34 cells.
Notes: (A) 6.25 mg·mL−1 CO3 layered double hydroxide (LDH)–fluorescein isothiocyanate (FITC), incubated for 2.5 hours; (B) free 6.25 mg·mL−1 FITC anions incubated for 4 hours. Reproduced from Li SD, Li JH, Wang CL, et al. Cellular uptake and gene delivery using layered double hydroxide nanoparticles. J Mater Chem B. 2013:61–68, with permission of The Royal Society of Chemistry.162
Biomedical application of layered double hydroxides (LDHs)
| Sample | Type of formulation | Name of formulation | Type of disease | Reference(s) |
|---|---|---|---|---|
| 1 | Anticancer formulation | Methotrexate LDHs | Bone cancer, leukemia, etc | Zhang et al, |
| 2 | Ifosfamide LDHs | Pediatric, adult tumors, soft-tissue sarcomas and lymphomas | Nie and Hou | |
| 3 | Camptothecin LDHs | Lung cancer, ovarian cancer, pancreatic cancer, stomach cancer | Wu et al | |
| 4 | Protocatechuic acid LDHs | Cervix, breast, human leukemia (pa-2000-leukemia), liver, lungs, prostate | Barahuie et al | |
| 5 | Etoposide–Mg/Al LDHs | Small-cell lung carcinoma, gastric cancer cells, hematologic malignancies, childhood malignancies, germ-cell tumors | Qin et al | |
| 6 | Ciprofloxacin LDH | Adenocarcinomic human alveolar basal epithelial cancer cell line to demonstrate synergistic effect | Latip et al | |
| 7 | Antimicrobial formulation | Ciprofloxacin LDH | Hesse et al | |
| 8 | Hippuric acid ZnLH | Hussein et al | ||
| 9 | Benzylpenicillin–Mg/Al LDHs | Wang et al | ||
| 10 | Amino acid–Mg/Al LDHs | Valarezo et al | ||
| 11 | Antimicrobial biomaterial | Ag-Zn/Al LDHs | Mishra et al | |
| 12 | AgNPbio-Mg/Al LDHs | Marcato et al | ||
| 13 | AgNP-Zn/Al LDHs | Carja et al | ||
| 14 | Zn-Ti LDHs | Zhao et al | ||
| 15 | ZnoNP-Zn/Al LDHs | Zhang et al | ||
| 16 | Antituberculosis formulation | PAS ZnLH | Saifullah et al | |
| 17 | Antituberculosis formulation | PAS–Zn/Al LDHs | Saifullah et al | |
| 18 | Isoniazid–Zn/Al LDHs | Saifullah et al | ||
| 19 | Isoniazid–Mg/Al LDHs | Saifullah et al | ||
| 20 | Sunscreen formulation | Cinnamic acid ZnLHs | Protection from UV radiation | Mohsin et al |
| 21 | Cinnamic acid–Zn/Al LDHs | Protection from UV radiation | Mohsin et al | |
| 22 | Benzophenone-4–Zn/Al LDHs | Protection from UV radiation | Mohsin et al | |
| 23 | Eusolex® 232–Zn/Al LDHs | Protection from UV radiation | Mohsin et al | |
| 24 | Benzophenone-9–Zn/Al LDHs | Protection from UV radiation | Mohsin et al | |
| 25 | UV-protective coating material | Fe3+ with Mg/Al LDH polysiloxanes | Protection from UV radiation | Wang et al |
| 26 | 2,4-dihydroxybenzophenone dodecylbenzenesulfonate LDHs | Protection from UV radiation | Li et al | |
| 27 | Gene-delivery formulation | pEGFP-N1 DNA LDHs | Transfected into mouse motor neuron cells (NSC 34) | Li et al |
| 28 | Plasmid DNA LDHs | COS7 cells and HepG2 cells | Hu et al | |
| 29 | Gene-delivery formulation | DNA LDHs | DNA protection in adverse environment of Cd2+/Pb2+ solution | Wu et al |
| 30 | Gene-delivery and anticancer formulation | siRNA LDHs | Enhanced siRNA stability | Zhang et al |
| 31 | siRNA–5-FU LDHs | Cancer treatment | Li et al | |
| 35 | siRNA LDHs | Transfected into cytoplasm of HEK293T cells | Ladewig et al |
Abbreviations: ZnLH, zinc layered hydroxides; NP, nanoparticle; PAS, para-aminosalicylic acid; UV, ultraviolet; DNA, deoxyribonucleic acid; siRNA, small interfering ribonucleic acid; 5-FU, fluorouracil.
Figure 11Release profiles of levodopa from the nanocomposite at pH 7.4 (A) and pH 4.8 (B).
Notes: Inset shows the release profiles of levodopa from the nanocomposite at pH 4.8 from 0 to 2,000 minutes. Reproduced with permission from Kura AU, Hussein Al Ali SH, Hussein MZ, Fakurazi S, Arulselvan P. Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomedicine. 2013;8:1103–1110.178
In vitro biocompatibility studies of layered double hydroxides (LDHs) toward various cell lines
| Sample | Type of LDH | Biocompatibility with cell type | Reference |
|---|---|---|---|
| 1 | Etoposide (VP16)–Mg/Al LDHs | Human GES-1 cells | Qin et al |
| 2 | Perindopril erbumine LDHs | Human liver cell line | Hussein et al |
| 3 | pEF-eGFP LDHs | HEK 293T cells | Xu et al |
| 4 | Protein gene LDHs | Monkey kidney (Vero3) cells | Masarudin et al |
| 5 | Salicylic acid ZnLHs | Monkey kidney (Vero3) cells | Ramli et al |
| 6 | LDH-AgNPbio | Permanent lung fibroblast cell line (V79) | Marcato et al |
| 7 | Fibroblast 3T3 cells and human normal lung cells (MRC-5) | Saifullah et al | |
| 8 | Fibroblast 3T3 cells and human normal lung cells (MRC-5) | Saifullah et al | |
| 9 | Isoniazid–Mg/Al LDHs | Fibroblast 3T3 cells and human normal lung cells (MRC-5) | Saifullah et al |
| 10 | Isoniazid–Zn/Al LDHs | Fibroblast 3T3 cells and human normal lung cells (MRC-5) | Saifullah et al |
| 11 | Cinnamic acid ZnLH | Fibroblast cells (3T3) | Mohsin et al |
| 12 | Cinnamic acid into Zn/Al LDHs | HDF cells | Mohsin et al |
| 13 | Benzophenone-4–Zn/Al LDHs | HDF cells | Mohsin et al |
| Eusolex® 232–Zn/Al LDHs | HDF cells | Mohsin et al | |
| 14 | Benzophenone-9–Zn/Al LDHs | HDF cells | Mohsin et al |
| 15 | Ellagic acid ZnLH | Normal human breast epithelial MCF-10A cells and murine fibroblast 3T3 cells | Hussein-Al-Ali et al |
| 16 | Levodopa and Zn/Al LDHs | PC 12 cell model | Kura et al |
Abbreviations: NP, nanoparticle; ZnLHs, zinc layered hydroxides.
In vivo biocompatibility of layered double hydroxides (LDHs) using animal models
| Sample | Type of LDH | Animal model | Reference |
|---|---|---|---|
| 1 | Indomethacin–Mg/Al LDHs | Both sexes | Del Arco et al |
| 2 | Ketoprofen–Mg/Al LDHs | Mice | Silion et al |
| 3 | Ketoprofen–Zn/Al LDHs | Mice | Silion et al |
| 4 | Acetylsalicylic acid–dextran LDHs | Rabbits | Dong et al |
| 5 | LDH nanoparticles | Mice | Yu et al |
| 6 | Mg/Al LDH nanoparticles | Mice | Flesken-Nikitin et al |
| 7 | Levodopa–Zn/Al LDHs | Rats | Kura et al |